Skip to content

    Godrej Agrovet

    GODREJAGRONeutral
    Fast Moving Consumer Goods·7 Aug 2025
    Management Summary

    Godrej Agrovet started FY26 on a strong note, with double-digit growth in revenue and profits, primarily driven by an exceptional performance in the Vegetable Oil segment and a significant turnaround in Astec LifeSciences. However, the quarter also highlighted challenges, with the Crop Protection business facing weather-related headwinds for its key herbicide products and the Dairy segment experiencing margin pressure from rising costs. The core Animal Feed business demonstrated robust volume demand, but pricing power remains a key monitorable. Management's focus is clearly on portfolio premiumization and operational efficiencies to navigate the mixed environment across its diverse business segments.

    Highlights

    8

    • Consolidated revenue from operations grew 11% YoY to ₹2,614 crore.

    • Profit Before Tax (PBT) increased by 24.5% YoY to ₹188 crore.

    • Vegetable Oil segment was the standout performer, with Fresh Fruit Bunch (FFB) arrivals surging 50% YoY.

    • Astec LifeSciences showed strong recovery with a 31% YoY revenue growth and is guided to be EBITDA break-even for FY26.

    • Animal Feed segment reported a healthy 8% volume growth, though revenues and margins remained flat due to lower realizations.

    • Crop Protection segment revenue grew marginally by 5%, but profitability was impacted by erratic weather affecting key products.

    • Dairy segment revenues were flat, with EBITDA margins declining due to higher milk procurement prices and increased ad spends.

    • The share of live birds in the Poultry business has been strategically reduced to 15% of sales, with 85% now from value-added products.

    Concerns

    1

    • Crop Protection Sales Returns

    What Changed2

    vs Q2 FY26

    Guidance items5 → 8 (+3)Risks discussed3 → 4 (+1)

    Key financials

    Single quarter

    02 metrics
    1. 01Revenue from Operations₹2,614 Cr+11.2%YoY
    2. 02Profit Before Tax₹188 Cr+24.5%YoY

    Segment breakdown

    Animal Feed
    8% Volume Growth0% Revenue Growth
    Vegetable Oil
    50% FFB Arrivals Growth1,78,000 tons FFB Arrivals (Q1'26)18.4% Oil Extraction Ratio (Q1'26)
    Crop Protection (Standalone)
    5% Revenue Growth
    Astec LifeSciences
    31% Revenue Growth
    Dairy
    0% Revenue Growth2% Milk Volume Growth
    Poultry and Processed Food
    — Revenue
    ACI Godrej (Bangladesh JV)
    -20% Revenue Decline
    List

    Guidance & targets

    8
    CategoryTargetPriority
    Revenue
    Consolidated Top-line Growth
    early teens %
    		Medium
    Revenue
    Astec LifeSciences Turnover
    ₹500 crores
    		High
    Revenue
    Astec CDMO Business Revenue
    Over ₹300 crores
    		High
    Margin
    Crop Protection EBIT Margin
    28% to 30%
    		High
    Margin
    Dairy Business EBITDA (post ad-spend)
    6% to 7%
    		High
    Profitability
    Astec LifeSciences EBITDA
    Break-even
    		High
    Volume
    Vegetable Oil FFB Arrival Growth
    15% to 18%
    		High
    Other
    Dairy VAP Salience
    50%
    		Medium

    Risks & concerns

    5
    RiskSeverity

    Crop Protection Sales Returns

    Erratic rainfall has negatively impacted the season for key herbicide products (Hitweed Maxx), and management explicitly expects sales returns from the channel, which could hurt Q2 profitability. — Management acknowledged

    high

    Margin Pressure in Dairy Segment

    EBITDA margins declined due to a combination of increased milk procurement prices and higher advertising spends, a trend that could persist. — Management acknowledged

    medium

    Increased Competition in Crop Protection

    The principal for a key product, Gracia, is now supplying directly to a competitor, which has increased pricing pressure and reduced the product's salience. — Management acknowledged

    medium

    Muted Realizations in Animal Feed

    Despite strong 8% volume growth, the segment's revenue and margins were flat, indicating a lack of pricing power in the current environment. — Management acknowledged

    medium

    Areas of Evasion(1)

    • While acknowledging the risk of sales returns in Crop Protection, management was unable to provide a quantitative estimate of the potential impact, citing seasonal uncertainty.

    Q&A highlights

    3

    “So, we still maintain that we will have returns. It is the tail end of the season. But the only thing is that last year also we had seen that surprisingly our liquidation was much more than what we expected. So, that is why we are a little cautious. But I still reiterate that the returns will be more than expected.”

    This confirms a key near-term risk for the company, acknowledging that the poor season for Hitweed will lead to product returns from the channel, potentially impacting Q2 results.

    asked by Aejas Lakhani

    2 min read6 chapters

    Detailed Narrative

    01

    Overall Performance: A Tale of Two Halves

    Godrej Agrovet posted a solid Q1 FY26, with consolidated revenue rising 11% YoY to ₹2,614 crore and PBT jumping 25% to ₹188 crore. The strong headline numbers were largely driven by the Vegetable Oil and Astec LifeSciences segments. However, this masked challenges elsewhere, with the core Animal Feed business seeing flat revenue despite volume growth, and the Crop Protection and Dairy segments facing significant margin and operational headwinds.

    02

    Vegetable Oil Segment: The Star Performer

    The Vegetable Oil business delivered an exceptional quarter. Fresh Fruit Bunch (FFB) arrivals surged by 50% YoY, with Q1 volumes reaching 178k tons. The Oil Extraction Ratio (OER) also improved to 18.37% from 17.98% last year. Management is guiding for a full-year FFB arrival growth of 15-18%. The company is also pushing for value-addition, with 80% of sales now from value-added products and new PKO refinery and inter-esterification capacities coming online in Q3 and Q4.

    03

    Astec LifeSciences: Turnaround on Track

    Astec LifeSciences showed strong signs of recovery, with revenue growing 31% YoY. Management provided confident guidance for the full year, targeting an EBITDA break-even and a turnover of ₹500 crores for FY26. The strategic shift towards the CDMO business is accelerating, with a revenue target of over ₹300 crores for FY26, expected to constitute 65% of total sales. The proceeds from a recent rights issue have been used to repay debt, strengthening the balance sheet.

    04

    Crop Protection: Weather Woes and Competitive Heat

    The Crop Protection segment faced a difficult quarter. Revenue grew a marginal 5%, but profitability was hit by an erratic monsoon that disrupted the application window for its key herbicide, Hitweed Maxx. Management acknowledged the high probability of sales returns from the channel, posing a risk to Q2 results. Furthermore, competitive intensity for another key product, Gracia, has increased as the principal now supplies directly to a competitor, impacting its salience which stood at 5% in Q1 vs 18% for the full year FY25.

    05

    Animal Feed & Dairy: Volume Growth Meets Margin Pressure

    The Animal Feed business, a key volume driver, grew 8% YoY, led by Broiler (13%) and Cattle feed (11%). However, lower realizations kept revenue and margins flat, highlighting pricing challenges. The Dairy segment saw flat revenues despite a 2% increase in milk volumes. EBITDA margins declined due to higher milk procurement costs and a ₹5 crore YoY increase in advertising spends, reflecting the investment-heavy nature of brand building in this category.

    06

    Strategic Update: Consolidation and Future Moves

    Management highlighted a significant strategic step taken in the last six months: an investment of ₹1,250 crores to buy out partners and gain 100% ownership of Godrej Foods and Creamline Dairy. This move provides greater operational flexibility for future portfolio decisions. Management hinted that this was a foundational step, advising analysts to 'keep glued on more to follow', suggesting further corporate restructuring could be on the horizon.

    This is an AI-generated summary of a publicly available earnings call transcript. It is for informational purposes only and does not constitute investment advice, a recommendation, or an endorsement. inve.money is not a SEBI-registered investment advisor. Please consult a qualified financial advisor before making any investment decisions.